HCP 08
Oncology Pharmacist · France · Lead pharmacist
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Discussion summary
Focused on tolerability, dose management and adherence; measured on efficacy claims.
Key themes
Pre / post perception
Overall perception shiftPre-congress vs post-congress
3 improved · 1 declined
Perception of clinical efficacy
Confidence in the evidence
Safety / tolerability perception
Likelihood to prescribe
Familiarity with treatment
Competitive perception
Illustrative synthetic measures. Movement is shown as an observed pre/post shift, not a causal effect of the congress.
KBQs discussed
Position against each predefined questionClinical significance of the primary endpoint
What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?
“There is a genuine signal here; I would just like to see durability over longer follow-up.”
Safety, tolerability and willingness to prescribe
How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?
“I would prescribe it, provided we have a realistic monitoring pathway in place.”
Use in node-positive populations
What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?
“The real-world benefit depends on whether patients can actually stay on it.”
Sequencing after adjuvant recurrence
How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?
“My instinct after recurrence is to change mechanism of action.”
Compelling nature of the primary endpoint
How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?
“It is a welcome result, but on its own it does not yet displace what I use first.”
Perception of safety and tolerability
How do experts perceive the safety and tolerability profile demonstrated in the trial?
“These are events we can manage within normal practice.”